Literature DB >> 20500153

Kv1.5-Kv beta interactions: molecular determinants and pharmacological consequences.

Teresa González1, Miren David, Cristina Moreno, Alvaro Macías, Carmen Valenzuela.   

Abstract

Kv1.5 channels are homotetramers of alpha-pore subunits mainly present in human atrium and pulmonary vasculature. Thus, Kv1.5 is a pharmacological target for cardiovascular diseases. Kv beta 1.3 assemblies with Kv alpha 1.5 and modifies its gating and pharmacology. A further knowledge of alpha-beta interactions and pharmacology will lead a better design of new drugs.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20500153     DOI： 10.2174/138955710791384018

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  6 in total

1.  Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.

Authors:  Imju Jeong; Shin Hee Yoon; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-04-27       Impact factor: 3.000

2.  Regulation of Voltage-Gated K+ Channel Kv1.5 by the Janus Kinase JAK3.

Authors:  Jamshed Warsi; Bernat Elvira; Rosi Bissinger; Zohreh Hosseinzadeh; Florian Lang
Journal:  J Membr Biol       Date:  2015-06-23       Impact factor: 1.843

3.  SPAK and OSR1 sensitivity of voltage-gated K+ channel Kv1.5.

Authors:  Bernat Elvira; Jamshed Warsi; Carlos Munoz; Florian Lang
Journal:  J Membr Biol       Date:  2014-10-15       Impact factor: 1.843

Review 4.  Novel molecular targets for atrial fibrillation therapy.

Authors:  Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

5.  PKC inhibition results in a Kv 1.5 + Kv β1.3 pharmacology closer to Kv 1.5 channels.

Authors:  A Macías; A de la Cruz; A Prieto; D A Peraza; M M Tamkun; T González; C Valenzuela
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

6.  KV1.5-KVβ1.3 Recycling Is PKC-Dependent.

Authors:  Alvaro Macias; Alicia de la Cruz; Diego A Peraza; Angela de Benito-Bueno; Teresa Gonzalez; Carmen Valenzuela
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.